Table 1.

Statistical analysis for in vivo efficacy studies in PDXs from COG-N-453x and Felix cells, and xenografts from SH-SY5Y and NB-1643 cells

Tumor volumeEFS
PDX or xenograft (mutation)ALK statusMYCN statusTreatmentP value vs. vehicle controlP value vs. crizotinibP value vs. vehicle controlP value vs. crizotinib
COG-N-453xMutated: F1174LAmplifiedCrizotinib<0.0001<0.0001
PF-06463922<0.0001<0.0001<0.00010.0118
Felix-PDXMutated: F1245CNonamplifiedCrizotinib<0.00010.0008
PF-06463922<0.0001<0.0001<0.0001<0.0001
SH-SY5YMutated: F1174LNonamplifiedCrizotinib0.00110.0502
PF-06463922<0.0001<0.0001<0.00010.0003
NB-1643Mutated: R1275QAmplifiedCrizotinib<0.0001<0.0001
PF-06463922<0.0001<0.0001<0.00010.1464